EloraTZP Explained: Why Amylin + GIP/GLP-1 Is the Next Metabolic Research Frontier
New Phase 2b EloraTZP data combine eloralintide's amylin pathway with tirzepatide's GIP/GLP-1 activity. Here's what the 48-week results show and what Phase 3 must answer.
Retatrutide Phase 3 Results: What the New TRIUMPH-2 Data Show
Detailed Phase 3 TRIUMPH-2 results put retatrutide back in focus. Here is what the weight-loss and A1C data show, how the triple agonist works, and the key limitations.
Can You Be Fit and Still Have Heart Risk? World Heart Day 2026
World Heart Day 2026 asks active adults to look beyond appearance. Learn why fitness does not replace blood pressure, cholesterol, glucose, and family-history awareness.